JMP Securities Reiterates Market Outperform on Iovance Biotherapeutics, Maintains $18 Price Target

Benzinga · 09/15/2023 12:28
JMP Securities analyst Reni Benjamin reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and maintains $18 price target.